On December 8, 2020 Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, reported that it will release financial results for its fiscal 2020 fourth quarter ended September 30, 2020 after market close on Thursday, December 17, 2020 (Press release, Applied DNA Sciences, DEC 8, 2020, View Source [SID1234572434]). In conjunction with the release, the Company has scheduled a conference call at 4:30 p.m. Eastern Standard Time that will also be broadcast live over the Internet.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

What: Applied DNA’s Fiscal 2020 Fourth Quarter Financial Results Conference Call
When: Thursday, December 17, 2020, at 4:30 p.m. Eastern Standard Time
Where: Via phone by dialing +1-844-887-9402 (U.S toll free) or +1-412-317-6798 (international dialers) or via live webcast.

A telephonic replay of the conference call will be available for one week and may be accessed by calling +1-877-344-7529 (U.S. toll) or +1-412-317-0088 (international dialers) with the passcode 10149831. An archive of the webcast will be available for a period of one year on the ‘IR Calendar’ page of the Investor Relations section of the Company’s website starting within two hours from the conclusion of the live call.

On December 8, 2020 Axial Therapeutics Inc., a clinical-stage biotechnology company dedicated to building a unique class of gut-restricted therapeutics for central nervous system (CNS) disorders and conditions, reported that management will participate in a fireside chat at the 2020 RBC Capital Markets Healthcare Private Company Conference on Tuesday, December 15, 2020 at 8:40 AM EST (Press release, Axial Biotherapeutics, DEC 8, 2020, View Source [SID1234572432]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On December 8, 2020 EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, reported that it will effect a 1-for-10 reverse stock split at 5:00 p.m. Eastern Time (Press release, pSivida, DEC 8, 2020, View Source [SID1234572431]). Beginning with the opening of trading on December 9, 2020, EyePoint’s common stock will trade on the Nasdaq Global Market on a split-adjusted basis under a new CUSIP number 30233G209.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The reverse stock split is intended to enable EyePoint to regain compliance with the $1.00 minimum closing bid price required for continued listing on the Nasdaq Global Market.

At EyePoint’s special meeting of stockholders on December 1, 2020, EyePoint’s stockholders approved the proposal to authorize EyePoint’s Board of Directors to file an amendment to EyePoint’s certificate of incorporation to effect the reverse split at a ratio to be determined by the Board, ranging from 1-for-10 to 1-for-25. The specific 1-for-10 ratio was subsequently approved by EyePoint’s Board of Directors and the reverse stock split was effected by filing a Certificate of Amendment to EyePoint’s certificate of incorporation with the Secretary of State of the State of Delaware.

The reverse split will affect all issued and outstanding shares of EyePoint’s common stock. At the effective time of the reverse stock split the number of shares of common stock issued and outstanding will be reduced from approximately 151.3 million shares to approximately 15.13 million shares. All outstanding options, warrants, restricted stock units and deferred stock units entitling their holders to receive or purchase shares of EyePoint’s common stock will be adjusted as a result of the reverse split, as required by the terms of each security. The number of shares reserved for future issuance pursuant to EyePoint’s 2016 Long-Term Incentive Plan and the number of shares reserved for future issuance pursuant to EyePoint’s 2019 Employee Stock Purchase Plan will also be appropriately adjusted. The reverse stock split will affect all stockholders uniformly and will not affect any stockholder’s ownership percentage of EyePoint’s shares (except to the extent that the reverse stock split would result in some of the stockholders receiving cash in lieu of fractional shares). Stockholders will receive cash in lieu of fractional shares based on today’s closing sales price of EyePoint’s common stock as quoted on the Nasdaq Global Market. The reverse stock split will not reduce the number of authorized shares of common stock, or preferred stock, or change the par values of EyePoint common stock (which will remain at $0.001 per share) or preferred stock (which will remain at $0.001 per share).

Computershare Trust Company, N.A. (Computershare) is acting as the exchange agent and transfer agent for the reverse stock split. Computershare will provide instructions to stockholders with physical certificates regarding the process for exchanging their pre-split stock certificates for post-split shares in book-entry form and receiving payment for any fractional shares.

On December 8, 2020 Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, reported that it has completed patient enrollment in its Phase 1 trial evaluating the safety and tolerability of SBP-101 when used in combination with standard of care agents gemcitabine and nab-paclitaxel for first-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDA) (Press release, Sun BioPharma, DEC 8, 2020, View Source [SID1234572430]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The trial, which included a dose escalation phase and an expansion phase, enrolled 50 patients, 30 of whom were treated using the dose and schedule that will advance to a randomized trial of the combination versus gemcitabine and nab-paclitaxel alone planned to begin in the first half of 2021. In total, the safety of SBP-101 has been evaluated in 79 patients in two clinical trials.

"We are pleased to have completed enrollment in our Phase 1b trial and expect to announce data in the first half of next year," commented Jennifer Simpson, PhD., M.S.N., C.R.N.P.-President & Chief Executive Officer. "Completing enrollment for SBP-101 marks an important milestone in our quest to bring new therapeutic options to patients with pancreatic cancer, which is an orphan disease and an area of unmet medical need."

SBP-101 is currently being evaluated in a Phase 1a/1b clinical trial of patients with previously untreated metastatic PDA at sites in the United States and Australia. SBP-101 has received Fast Track and orphan drug designation from FDA. For more information, please visit clinicaltrials.gov.

About SBP-101
SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma. The molecule has shown signals of tumor growth inhibition in clinical studies of US and Australian metastatic pancreatic cancer patients, suggesting complementary activity with an existing FDA-approved chemotherapy regimen. In clinical studies to date, SBP-101 has not shown exacerbation of the typical chemotherapy-related adverse events of bone marrow suppression and peripheral neuropathy. The safety data and PMI profile observed in the current Panbela sponsored current clinical trial provides support for continued evaluation of the compound in a randomized clinical trial. For more information, please visit View Source

On December 8, 2020 The board of directors of Targovax ASA (OSE:TRVX) ("Targovax" or the "Company") reported that resolved to increase the share capital of the Company following the completion of an exercise period for vested share options under the Company’s long-term incentive program for employees (Press release, Targovax, DEC 8, 2020, View Source [SID1234572429]). The exercise period for the employee options commenced on 3 December 2020 at 11:00 hours (CET) and ended on 8 December 2020 at 11:00 hours (CET).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Exercise of options

In total, 10,726 options were exercised, giving the option holders the right to subscribe for 10,726 shares, each with a par value of NOK 0.10, at a subscription price of NOK 7.74 per share.

2. Resolutions to increase the share capital in Targovax ASA

The Company’s board of directors has on 8 December 2020, in accordance with the authorisation granted by the general meeting on 29 April 2020, resolved to increase the share capital with NOK 1,072.60 by the issuance of 10,726 new shares, each with a par value of NOK 0.10 in order to settle the exercise of options.

Accordingly, the new share capital of the Company is NOK 8,653,131.80, divided into 86,531,318 shares, each with a par value of NOK 0.10. The share capital increase will be registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret) as soon as practically possible after the share contribution has been fully paid.